A new class of radiosensitizers for glioblastoma
A new class of radiosensitizers for glioblastoma |
|
https://doi.org/10.18632/oncotarget.27970
Roger Abounader,
and David Schiff
|
| 1199-1200 |
A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection
A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection |
|
https://doi.org/10.18632/oncotarget.27982
Shay Sharon,
Jason R. Baird,
Shelly Bambina,
Gwen Kramer,
Tiffany C. Blair,
Shawn M. Jensen,
Rom S. Leidner,
R. Bryan Bell,
Nardy Casap,
Marka R. Crittenden,
and Michael J. Gough
|
| 1201-1213 |
Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma
Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma |
|
https://doi.org/10.18632/oncotarget.27992
Catherine T. Haring,
Chandan Bhambhani,
Collin Brummel,
Brittany Jewell,
Emily Bellile,
Molly E. Heft Neal,
Erin Sandford,
Ryan M. Spengler,
Apurva Bhangale,
Matthew E. Spector,
Jonathan McHugh,
Mark E. Prince,
Michelle Mierzwa,
Francis P. Worden,
Muneesh Tewari,
Paul L. Swiecicki,
and J. Chad Brenner
|
| 1214-1229 |
Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study
Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study |
|
https://doi.org/10.18632/oncotarget.27991
Anjali Gupta,
Taofik Oyekunle,
Omolola Salako,
Adetola Daramola,
Olusegun Alatise,
Gabriel Ogun,
Adewale Adeniyi,
April Deveaux,
Veeral Saraiya,
Allison Hall,
Omobolaji Ayandipo,
Thomas Olajide,
Olalekan Olasehinde,
Olukayode Arowolo,
Adewale Adisa,
Oludolapo Afuwape,
Aralola Olusanya,
Aderemi Adegoke,
Trygve O. Tollefsbol,
Donna Arnett,
Michael J. Muehlbauer,
Christopher B. Newgard,
H3 Africa Kidney Research Network,
and Tomi Akinyemiju
|
| 1230-1242 |
Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells
Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells |
|
https://doi.org/10.18632/oncotarget.27989
Andrew E. Greenstein,
and Hazel J. Hunt
|
| 1243-1255 |
Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target
Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target |
|
https://doi.org/10.18632/oncotarget.27981
Natsumi Hayashi,
Akitaka Yamasaki,
Shiho Ueda,
Shogo Okazaki,
Yoshiya Ohno,
Toshiyuki Tanaka,
Yuichi Endo,
Yoshihisa Tomioka,
Kazue Masuko,
Takashi Masuko,
and Reiko Sugiura
|
| 1256-1270 |
TERT and its binding protein: overexpression of GABPA/B in high grade gliomas
TERT and its binding protein: overexpression of GABPA/B in high grade gliomas |
|
https://doi.org/10.18632/oncotarget.27985
Efthymios Papazacharias,
Saskia Kuhl,
Gabriele Röhn,
Lukas Görtz,
Roland Goldbrunner,
and Marco Timmer
|
| 1271-1280 |
Cross-talks in colon cancer between RAGE/AGEs axis and inflammation/immunotherapy
Cross-talks in colon cancer between RAGE/AGEs axis and inflammation/immunotherapy |
|
https://doi.org/10.18632/oncotarget.27990
Annachiara Mollace,
Maria Laura Coluccio,
Giuseppe Donato,
Vincenzo Mollace,
and Natalia Malara
|
| 1281-1295 |
Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors
Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors |
|
https://doi.org/10.18632/oncotarget.27988
Shilpa S. Dhar,
and Min Gyu Lee
|
| 1296-1308 |
Targeting super-enhancers reprograms glioblastoma central carbon metabolism
Targeting super-enhancers reprograms glioblastoma central carbon metabolism |
|
https://doi.org/10.18632/oncotarget.27938
Trang T.T. Nguyen,
Mike-Andrew Westhoff,
Georg Karpel-Massler,
and Markus D. Siegelin
|
| 1309-1313 |
Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia
Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia |
|
https://doi.org/10.18632/oncotarget.27919
Jan Philipp Bewersdorf,
and Amer M. Zeidan
|
| 1314-1317 |
The formation of pre-effectors in the steady state opens a new perspective for cancer immunosurveillance
The formation of pre-effectors in the steady state opens a new perspective for cancer immunosurveillance |
|
https://doi.org/10.18632/oncotarget.27967
Alexey Surnov,
and Daniel Hawiger
|
| 1318-1320 |
Mechanisms of gefitinib-induced interstitial pneumonitis: why and how the TKI perturbs innate immune systems?
Mechanisms of gefitinib-induced interstitial pneumonitis: why and how the TKI perturbs innate immune systems? |
|
https://doi.org/10.18632/oncotarget.27958
Tomohiro Kagi,
Takuya Noguchi,
and Atsushi Matsuzawa
|
| 1321-1322 |
Correction: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma
Correction: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma |
|
https://doi.org/10.18632/oncotarget.28001
M. Herman Chui,
Susanne K. Kjaer,
Kirsten Frederiksen,
Charlotte G. Hannibal,
Tian-Li Wang,
Russell Vang,
and Ie-Ming Shih
|
| 1323-1324 |
Correction: Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer
Correction: Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer |
|
https://doi.org/10.18632/oncotarget.28004
Edna Gordian,
Eric A. Welsh,
Nicholas Gimbrone,
Erin M. Siegel,
David Shibata,
Ben C. Creelan,
William Douglas Cress,
Steven A. Eschrich,
Eric B. Haura,
and Teresita Muñoz-Antonia
|
| 1325-1325 |
